These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35938508)

  • 1. Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
    Yang J; Chang Y; Tien JC; Wang Z; Zhou Y; Zhang P; Huang W; Vo J; Apel IJ; Wang C; Zeng VZ; Cheng Y; Li S; Wang GX; Chinnaiyan AM; Ding K
    J Med Chem; 2022 Aug; 65(16):11066-11083. PubMed ID: 35938508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader.
    Zhou L; Zhou K; Chang Y; Yang J; Fan B; Su Y; Li Z; Mannan R; Mahapatra S; Ding M; Zhou F; Huang W; Ren X; Xu J; Wang GX; Zhang J; Wang Z; Chinnaiyan AM; Ding K
    J Med Chem; 2024 Oct; 67(20):18247-18264. PubMed ID: 39388374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
    Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
    Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
    Quereda V; Bayle S; Vena F; Frydman SM; Monastyrskyi A; Roush WR; Duckett DR
    Cancer Cell; 2019 Nov; 36(5):545-558.e7. PubMed ID: 31668947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition.
    Chang Y; Wang X; Yang J; Tien JC; Mannan R; Cruz G; Zhang Y; Vo JN; Magnuson B; Mahapatra S; Cho H; Dhanasekaran SM; Wang C; Wang Z; Zhou L; Zhou K; Zhou Y; Zhang P; Huang W; Xiao L; Liu WR; Hamadeh R; Su F; Wang R; Miner SJ; Cao X; Cheng Y; Mehra R; Ding K; Chinnaiyan AM
    Cell Rep Med; 2024 Oct; 5(10):101752. PubMed ID: 39353441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and resistance mechanism of a selective CDK12 degrader.
    Jiang B; Gao Y; Che J; Lu W; Kaltheuner IH; Dries R; Kalocsay M; Berberich MJ; Jiang J; You I; Kwiatkowski N; Riching KM; Daniels DL; Sorger PK; Geyer M; Zhang T; Gray NS
    Nat Chem Biol; 2021 Jun; 17(6):675-683. PubMed ID: 33753926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer.
    Zhang L; Zhen Y; Feng L; Li Z; Lu Y; Wang G; Ouyang L
    Eur J Med Chem; 2023 Nov; 259():115648. PubMed ID: 37478560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.
    Cheng L; Zhou S; Zhou S; Shi K; Cheng Y; Cai MC; Ye K; Lin L; Zhang Z; Jia C; Xiang H; Zang J; Zhang M; Yin X; Li Y; Di W; Zhuang G; Tan L
    Cancer Res; 2022 Oct; 82(19):3588-3602. PubMed ID: 35857807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer.
    Nie HJ; Li BF; Sun J; Yuan Y; Zhang ZG; Hu H; Wang WJ; Chen Z; Wang S; Huang W; Diao X; Yu J; Huang R; Chen XH
    Bioorg Chem; 2024 Dec; 153():107876. PubMed ID: 39406109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13.
    Liu Y; Hao M; Leggett AL; Gao Y; Ficarro SB; Che J; He Z; Olson CM; Marto JA; Kwiatkowski NP; Zhang T; Gray NS
    J Med Chem; 2020 Jul; 63(13):6708-6726. PubMed ID: 32502343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
    Zhang T; Kwiatkowski N; Olson CM; Dixon-Clarke SE; Abraham BJ; Greifenberg AK; Ficarro SB; Elkins JM; Liang Y; Hannett NM; Manz T; Hao M; Bartkowiak B; Greenleaf AL; Marto JA; Geyer M; Bullock AN; Young RA; Gray NS
    Nat Chem Biol; 2016 Oct; 12(10):876-84. PubMed ID: 27571479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer.
    Wu Y; Wu M; Zheng X; Yu H; Mao X; Jin Y; Wang Y; Pang A; Zhang J; Zeng S; Xu T; Chen Y; Zhang B; Lin N; Dai H; Wang Y; Yao X; Dong X; Huang W; Che J
    Bioorg Chem; 2024 Jan; 142():106952. PubMed ID: 37952486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
    Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
    J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2.
    Dale B; Anderson C; Park KS; Kaniskan HÜ; Ma A; Shen Y; Zhang C; Xie L; Chen X; Yu X; Jin J
    ACS Pharmacol Transl Sci; 2022 Jul; 5(7):491-507. PubMed ID: 35837138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma.
    Jiang B; Jiang J; Kaltheuner IH; Iniguez AB; Anand K; Ferguson FM; Ficarro SB; Seong BKA; Greifenberg AK; Dust S; Kwiatkowski NP; Marto JA; Stegmaier K; Zhang T; Geyer M; Gray NS
    Eur J Med Chem; 2021 Oct; 221():113481. PubMed ID: 33945934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
    Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
    Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Degradation of MLK3 by a Novel CEP1347-VHL-02 PROTAC Compound Limits the Oncogenic Potential of TNBC.
    Karpińska K; Mehlich D; Sabbasani VR; Łomiak M; Torres-Ayuso P; Wróbel K; Truong VN; Serwa R; Swenson RE; Brognard J; Marusiak AA
    J Med Chem; 2024 Sep; 67(17):15012-15028. PubMed ID: 39207123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current progress and novel strategies that target CDK12 for drug discovery.
    Lei P; Zhang J; Liao P; Ren C; Wang J; Wang Y
    Eur J Med Chem; 2022 Oct; 240():114603. PubMed ID: 35868123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical degrader enhances the treatment of androgen receptor-positive triple-negative breast cancer.
    Wu Y; Xue J; Li J
    Arch Biochem Biophys; 2022 May; 721():109194. PubMed ID: 35337811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2.
    Velez J; Dale B; Park KS; Kaniskan HÜ; Yu X; Jin J
    Eur J Med Chem; 2024 Mar; 267():116154. PubMed ID: 38295690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.